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ABSTRACT
IN VIVO INVESTIGATIONS OF POLYMER
CONJUGATES AS THERAPEUTICS
SEPTEMBER 2011
ELIZABETH M. HENCHEY
B.S. UNIVERSITY OF MASSACHUSETTS AMHERST
M.S. UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Sallie Smith Schneider
Polymer conjugates offer a way to introduce materials into the body that would
normally be rejected or cause toxicity. Two polymers are investigated in vivo for uses
in chemotherapeutic delivery, protein therapeutics, and DNA transfection. A novel
polymer, polyMPC, has the ability to increase doxorubicin loading and its solubility,
and is conjugated in a way to release its payload in a low pH environment. Through
its conjugation, blood clearance time of doxorubicin is increased, and thus tumor
exposure to the drug is increased with a single administration. It can be administered
at ten times the concentration of free doxorubicin, and three times the concentration of
Doxil®, while decreasing the cardio-toxicity normally associated with doxorubicin
administration. These results show that polyMPC has the potential to increase
treatment efficacy of doxorubicin. With increased circulation time, MPC polymers
have additional potential for protein delivery and variations of its design were tested
in linear, branched and grafted states, which show limited affect on tissue weight. An
additional polymer for use in DNA transfection, NLS2, demonstrated its lack of tissue
toxicity when injected intramuscularly. While continued investigation into these
polymers is required, this initial data indicates their promising uses as therapeutics.
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CHAPTER 1
INTRODUCTION

Current chemotherapeutic cancer treatment options are accompanied by adverse side
effects that reduce the administrable drug concentration and thus the chances for a
successful treatment response. Prodrugs are nanosized, polymer-drug conjugates that
offer a way to increase drug dosage concentrations. They prevent toxicity of the drug
by releasing it from the polymer following hydrolysis or enzymolysis at the drug to
polymer linkage point (Kratz et al. 2008). Polymers can increase a drug's
hydrodynamic size, which allows longer circulation time in the blood stream and
greater drug accumulation in the tumor environment through the enhanced permeation
and retention (EPR) effect (Veronese et al. 2008). The EPR effect describes the more
open, or leaky, vasculature of tumor environments, which allows the permeation of
larger molecules than normal tissue environments would allow (Greish et al. 2007).
The poor lymphatic drainage of tumor environments allows retention of these
molecules, increasing exposure time of the tumor environment to the conjugated
chemotherapeutic (Greish et al. 2007).

A common drug linkage is the covalent attachment of poly(ethylene glycol) (PEG),
which increases a drug's water solubility, leading to an increase in drug dosage
concentrations in normally hydrophobic chemotherapeutics such as doxorubicin
(Veronese et al. 2008). However, PEGylation alone is not sufficient to reach the high
level of drug loading required for increased therapeutic results. A phosphorylcholine
(MPC) polymer designed by Dr. Todd Emrick (University of Massachusetts Amherst
Polymer Science Department), provides hydrophobic drugs like doxorubicin with
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high water solubility as well as increased drug loading (Emrick Lab Data, 2010). A
poly(methacryloyloxyethyl phosphorylcholine) (polyMPC)-doxorubicin conjugate of
Dr. Emrick's design has shown promise in its use as a chemotherapeutic conjugate
(Emrick, 2011). In vitro experiments show polyMPC-doxorubicin to be stable at a
normal physiological pH of 7.4 and instable, releasing its drug payload, at a low pH
indicative of tumor environments due to their release of lactic acid (Emrick Lab Data,
2010; Gerweck et al., 2006). This indicates that polyMPC-doxorubicin may be
appropriate for tumor site-specific release of doxorubicin.

A polyMPC polymer offers several advantages over other polymers currently under
investigation for chemotherapeutic delivery. Dendritic polymers, such as
polyamidoamine (PAMAM) and polypropyleneimine, are widely investigated, but
require surface modifications to avoid toxicity, while others, like polyaryl ether
dendrimers, require modifications to increase water solubility (Gillies et al., 2005). In
addition, the release of molecules can be difficult to control, not offering the
controlled release desirable in drug delivery; along with low hydrodynamic size
increases that do not allow utilization of the EPR effect (Jansen et al., 1995;
Nishikawa et al, 1996). Other investigated polymers, such as N-(2-Hydroxypropyl)
methacrylamide (HPMA), also carry risk of toxic accumulation. They are not
biodegradable and can accumulate in the skin through the reticuloendothelial system
(RES) (Duncan et al., 2010). The biggest drawback to both dendritic and HPMA
polymers is the complicated synthesis required to create and modify these polymers.
PolyMPC has a large advantage over these polymers in this regard, being synthesized
in a simple one-pot method.
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Protein therapeutics is another area of investigation for cancer treatment, along with
other diseases such as Hepatitis C. Obstacles facing protein therapeutic treatment is
high blood clearance times, preventing absorption and utilization of the proteins,
degradation due to immune response, and protein aggregation (Mero et al, 2011).
Polymers offer a way to circumvent the natural immune response by masking
proteins, and conjugation aids in preventing protein aggregation. The increased
circulation time afforded by Dr. Emrick’s phosphorylcholine methacrylate polymer
over conventional PEGylated polymers makes it a good candidate for protein
therapeutics.

A third important area of investigation for both cancers and additional diseases, such
as muscular dystrophy, is gene delivery. Efficient gene delivery is highly desirable,
yet a continued obstacle for scientists. Gene delivery would allow scientists to correct
altered gene expression, whether it be over-expression or lack of expression, which is
responsible for disease progression, therefore providing a cure for the disease.
Unfortunately, efficient gene delivery and incorporation has continued to elude
scientists to date. Polymers offer a way to increase cellular uptake of plasmids and
therefore increase the chances of plasmid incorporation and expression. An additional
polymer designed by Dr. Emrick has the potential to increase cellular uptake and
incorporation of DNA, while decreasing cell death (Parelkar et al., 2011).

To further investigate their potential, polyMPC was tested in vivo for its maximum
tolerated dose, cardio-toxicity, and biodistribution, MPC-protein polymers were tested
in three different architectures for in vivo tissue toxicity, and a transfection polymer,
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NLS2, was tested for its tissue toxicity and transfection efficiency into muscle.
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CHAPTER 2
MATERIALS AND METHODS

2.1 Polymers and Chemotherapeutics
The pMPC, pMPC-doxorubicin, and doxorubicin were kindly donated in powder
form by the Emrick Laboratory, Polymer Science and Engineering Department,
Univeristy of Massachusetts Amherst, stored at 4oC in the dark and kept dry. The
powders were weighed, Hank’s Balanced Salt Solution (HBSS) was added, and the
solutions vortexed until the powders were dissolved. Once dissolved, the solutions
were sterilized by filtration through a 0.2 µm pore filter and stored at 4oC until use.
Doxil® was also provided by the Emrick Laboratory and stored at 4oC until use.
NLS2 and JetPEI™ transfection polymers was provided by the Emrick Lab, stored at
-20oC, combined with GFP plasmid, and incubated for 1 hour at room temperature
immediately prior to injection. Protein therapeutic polymers (Lysozyme, linear MPC
polymer, branched MPC polymer, and grafted MPC polymer) conjugated to Alexa
Fluor® 546 (AF546) were supplied by the Emrick Lab and stored at -20oC until use.

2.2 Animal Models
Four to five-week old athymic nude mice (Nu/J) were purchased from Jackson
Laboratories (Stock #002019) and housed and treated in accordance with the
Institutional Animal Care and Use Committee. PolyMPC treatments were injected
into the left or right lateral tail vein and blood was collected from the submandibular
vein into 1.5 mL microcentrifuge tubes.
C57BL/6J mice were purchased from Jackson Laboratories (Stock #000664) and used
for both the protein polymer and transfection polymer experiments. Protein polymers
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were injection into the tails of 6 week old mice, and blood was collected from the tails
at 5, 10, 15, 30, 45, 60, and 120 minutes, 4, 6, 12, and 24 hours, and daily for 2 weeks
following injection. Transfection polymers were injected into the right anterior tibialis
muscle of 5 week old mice.

2.3 Cell Lines
MDA-MB-231 cells were cultured, either from previously frozen laboratory stocks or
recently purchased from ATCC (Catalogue #HTB-26), in Dulbecco’s Modified Eagle
Medium (DMEM) supplemented with 10% FBS and 1:500 gentamicin (MDAmedium). For in vivo experiments, cells were grown to ~80% confluence, harvested
with trypsin in log phase, and suspended to a concentration of 1x105 cells/uL in
HBSS. Cell suspensions were injected into the right flank of athymic nude mice at a
total volume of 100 uL and 1x 107 cells. Tumor volume was calculated by
L*W2*0.52.

2.4 Blood and Tissue Handling
Blood samples were allowed to clot on ice and then centrifuged at 1500 x g for 15
minutes. PolyMPC serum samples were collected and stored at 4oC until analyzed for
fluorescence excitation at 490 nm and emission at 590 nm, by high performance
liquid chromatography (HPLC) by Xiangji Chen. Tissues were collected post-mortem
and either fixed in 10% formalin for 24 hours at 4oC and paraffin embedded or frozen
in liquid nitrogen and stored at -80oC. Frozen tissues were weighed and then
homogenized in acidified isopropanol (90% isopropanol, 75mM HCL) and incubated
overnight at 4oC, followed by centrifugation at 1500 x g for 15 minutes. The liquid
supernatant was collected and stored at 4oC until analyzed for fluorescence excitation
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at 490 nm and emission at 590 nm, by HPLC by Xiangji Chen. Paraffin embedded
tissues were treated with hemotoxylin and eosin (H&E) stain and analyzed for tissue
architecture and cell staining patterns, or analyzed for apoptotic cells by TUNEL
using ApopTag® Plus Peroxidase In Situ Apoptosis Kit according to the provided
protocol.
At the end of 2 weeks protein polymer mice were euthanized and spleens, kidneys,
intestines, livers, lungs, and hearts were collected, weighed, and homogenized in
1XPBS. Tissue homogenates were centrifuged at 4oC at 1500 x g for 15 minutes and
stored at -20oC until analyzed for fluorescence by HPLC.
Transfection polymer tissues were collected after 4 weeks, fixed in 10% formalin for
24 hours at 4oC and paraffin embedded for sectioning. Tissue sections were treated
with GFP antibody and analyzed for positive staining or H&E stain and analyzed for
tissue architecture and cell staining patterns.
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CHAPTER 3
RESULTS

3.1 Maximum Tolerated Dose of polyMPC-Doxorubicin
PolyMPC-drug conjugates containing 30% doxorubicin by weight were tested in
doxorubicin doses of 10, 20, 30, 40, and 50 mg of doxorubicin per kg of body weight
to determine the maximum dose administrable without eliciting adverse effects. Seven
week old animals, three mice per group, received a single, intravenous injection in the
lateral tail vein of polyMPC-dox, polyMPC alone, or Hank's Balanced Salt Solution
(HBSS). The animals were weighed and examined daily for 30 days. Figure 1 shows
the weight changes in mice following treatment. A slight decrease in weight was
observed at day five in 30, 40, and 50 mg/kg dose groups, and shows that a single
injection at that dose may elicit some toxicity; however the mice were able to recover
from such toxicity, indicated by the return to normal weight ranges by day 24.
Necrosis around the injection site was observed these doses, most likely caused by
extravascular drug administration, and is the likely cause of the weight changes
observed in these mice. The results indicate that polyMPC can be used to increase the
concentration of doxorubicin without eliciting irreversible side effects.

PolyMPC drug conjugates were then compared to doses of free doxorubicin and
Doxil®, a commercially available liposome form of doxorubicin, in ten mice per
treatment group. Free doxorubicin was administered at a concentration of 6 mg/kg
and Doxil® was administered at a concentration of 10 mg/kg. A dose of 30 mg/kg
polyMPC-doxorubicin was chosen as that was the highest doxorubicin concentration
with the least observed toxicity in the previous experiment. Doxil®, polyMPC-
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doxorubicin, and HBSS were administered on day 0 and day 7, for a total doxorubicin
dose of 20 mg/kg in Doxil® and 60 mg/kg in polyMPC-doxorubicin; however free
doxorubicin was only administered on day 0 due to observed toxicity prior to and on
day 7 of treatment. The animals were weighed and examined daily for up to 54 days
(Figure 2). The results indicate that polyMPC-doxorubicin can be given at three times
the doxorubicin dose in Doxil®, and ten times the dose of free doxorubicin, while
exhibiting less toxicity-induced weight loss. On day 55, or upon presentation of
toxicity, hearts were collected, fixed in 10% formalin, and paraffin embedded. Tissue
sections were first analyzed for apoptotic cells by TUNEL (Figure 3). No apoptotic
were observed in these tissues. Due to lack of apoptotic cells present, cardiac tissues
were then treated with hematoxylin and eosin stain. Under 40x magnification, the
stained nuclei were counted per field of vision. The hearts of mice treated with free
doxorubicin show less nuclear staining per 40x field than the hearts of mice treated
with either HBSS, Doxil®, or polyMPC-doxorubicin (Figure 4 & 5). While actively
occurring death was not observed, likely due to the length of time following injection,
there seems to have been a loss of muscle cells due to doxorubicin, which was
prevented by conjugation to the polymers. These results provide evidence of the
decreased toxicity with increased drug dosage provided by polyMPC-doxorubicin.

3.2 Biodistribution and Clearance of polyMPC-Doxorubicin
The effect of polymer conjugation on the clearance of doxorubicin in animal serum
was tested on five-week old female athymic nude mice. The mice were divided
randomly into three groups and injected intravenously through the tail vein with
polyMPC-doxorubicin or free doxorubicin at 6 mg/kg, or with HBSS of the same
volume. Blood samples of 30-50 uL were taken at 0, 30 minutes, 2 hours, 6 hours, 12
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hours, 24 hours, 48 hours, and 72 hours post-treatment and analyzed for doxorubicin
fluorescence by HPLC. The results (Figure 6) indicate that polyMPC-doxorubicin has
a longer blood circulation time than that of free doxorubicin.

To examine the biodistribution of polyMPC-doxorubicin in comparison to free
doxorubicin, kidneys, livers, and hearts were collected after 72 hours from the mice
used for the clearance experiment and analyzed for doxorubicin fluorescence by
HPLC. The results (Figure 7) indicate there may have been accumulation of
polyMPC-doxorubicin in the liver and kidney to a greater extent than free
doxorubicin, although the variation between animals was considerably large and there
was no statistical difference in accumulation. In addition, H&E staining of livers did
not show any discernable differences in tissue architecture (Figure 8).

To observe tumor accumulation of polyMPC-doxorubicin versus free doxorubicin,
MDA-MB-231 cells were harvested with trypsin in log phase and suspended in HBSS
at a concentration of 1x107 / 100uL and injected into the right flank of six week old
athymic nude mice. Once the tumors reached a volume of 300-500 mm3, mice were
divided randomly into three groups of 2 mice and injected intravenously through the
tail vein with polyMPC-doxorubicin or free doxorubicin at 6 mg/kg, or with HBSS of
the same volume. At 12 hours and 24 hours post-treatment, the tumors were
collected, homogenized in acidified isopropanol, and analyzed for doxorubicin
fluorescence by HPLC (Figure 9). However, tumors did not grow in the majority of
mice injected with MDA-MB-231 cells, and though these results indicate that
polyMPC does not increase doxorubicin accumulation in the tumor, there was only
one mouse per group and no significant information can be obtained from this data.
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3.3 MPC-AF546 Affect on Tissue Weight
Six week old C57BLK/6J mice were injected into the tail with Lysozyme-AF546,
Linear MPC-AF546, Branched MPC-AF546, or Grafted MPC-AF546. Blood samples
and tissue homogenates were stored at -20oC for future HPLC analysis for AF546
fluorescence. Prior to homogenization, tissues were weighed, and tissue weights were
compared to see if there was statistical differences in tissue weight that may indicate
toxicity. When compared (Figure 10), there was a significant decrease in lung tissue
weight in the grafted polymer group compared to the PBS control (P=0.0038),
however there was no significant difference between tissue weights for the other
groups or tissues. This decrease in tissue weight may indicate an accumulation and
resultant toxicity of the grafted polymer in the lungs.

3.4 NSL2 Muscle Transfection
Five week old C57BLK/6J were injected with 10 uL into the proximal portion of the
anterior tibialis muscle, and 10 uL into the distal portion of the anterior tibialis
muscle, of either PBS, pEGFP, Jet-PEI-pEGFP (a commercially available linear
polyethylenimine tranfection reagent), or NLS2-pEGFP. Four weeks following
injection, the anterior tibialis muscles were collected, fixed in 10% formalin, and
paraffin embedded. Tissue sections were then treated with GFP antibody to determine
protein expression and transfection efficiency. There was not positive GFP staining
observed in any of the tissue sections (Figure 11). Sections were then stained with
hematoxylin and eosin for tissue architecture (Figure 12). The H&E staining indicates
there is no difference in tissue architecture between treatment groups, indicating that
NLS2 does not cause tissue toxicity upon direct injection into the muscle.
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CHAPTER 4
DISCUSSION & FUTURE DIRECTIONS

By conjugating doxorubicin to polyMPC, the maximum tolerated dose in mice is
increased by ten-fold over free doxorubicin and three-fold over Doxil®. Though some
weight loss was observed in mice, this was most likely due to experimenter error in
administration, not a cause of the polyMPC-doxorubicin, and recovery was observed
with return to normal weight ranges. In addition, the cardio-toxicity normally
associated with free doxorubicin treatment is circumvented through its conjugation to
polyMPC as evidenced through nuclear staining, and is presumably the cause of the
increase in the maximum tolerated dose in mice. The conjugation of doxorubicin to
polyMPC also increases the blood circulation time of doxorubicin, providing
increased exposure time of the drug with a reduced toxicity. We were not able to
demonstrate an accumulation of polyMPC-doxorubicin inside the tumor, however, as
there were not enough models to determine a lack of accumulation outside of
circumstance. Due to difficulty in growing the MDA-MB-231 xenografts, it is
possible that an unusual tumor environment was established that deviates in a way to
exclude the polyMPC-doxorubicin which would be effective in a normally formed
MDA-MB-231 xenograft. There was trend of increased accumulation of polyMPC in
the liver and kidneys, however not to a statistically significant amount, and it is
possible that this observation was the result of normal excretion of the drug conjugate,
and not extratumoral release of doxorubicin from the polymer. Because the tissues
were homogenized in acidified isopropanol to release doxorubicin from the polymer
for analysis, it is not possible to determine if the accumulated doxorubicin was free to
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elicit toxicity in these organs, or if it was still polymer bound and inactive. Since
there was no evidence of toxicity in these tissues, it is likely that the doxorubicin was
still conjugated and inactive.

The MPC-AF546 polymers showed varying results in tissue weights based on the
architecture of the polymers administered, however additional analysis of polymer
accumulation in tissues would need to be investigated before conclusions could be
drawn from this data. If polymer accumulation coincides with reduced tissue weight,
it is possible that the polymer is causing tissue toxicity and tissues should be
investigated for apoptosis and altered architecture.

NSL2 was shown not to cause toxicity when injected into the muscle; however
transfection of the pEGFP was also not demonstrated. This may be due to the length
of time from injection to tissue collection, and not an indication of failed transfection
as there was also no positive GFP staining from the JetPEI™ control.

In future, polyMPC-doxorubicin will be tested in vivo for tumor accumulation and
treatment efficacy on MDA-MB-231 xenografts to demonstrate its increased efficacy
over doxorubicin and Doxil® treatment. Serum samples and tissues from MPC-AF546
treated mice will be analyzed by HPLC to determine blood clearance times and tissue
accumulation of the various architectural forms of the polymer to determine its
efficacy in protein therapeutics. NSL2 will be tested in highly proliferative cell
environments, such as tumor and mammary tissues, to determine its transformation
efficiency, as well as being tested in varying polymer:DNA ratios to improve
transformation efficiency.
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Figure 1 Mouse Weights Following PolyMPC-Doxorubicin Treatment
Three mice per group were injected with 10, 20, 30, 40, or 50 mg of doxorubicin per
kg of body weight, or HBSS or empty polyMPC as controls. Mice were weighed and
examined for toxicity daily for 30 days. Daily mouse weights were averaged for each
group (n=3) and graphed above.
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Mouse Weight Following Doxorubicin Treatment
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Figure 2 Mouse Weights Following Doxorubicin Treatment
Ten mice per group were injected with the maximum tolerated dose of free
doxorubicin (6mg/kg), Doxil® (liposomal doxorubicin, 10 mg/kg), polyMPCdoxorubicin (30 mg/kg), or HBSS as a control. Mice were weighed and examined for
toxicity 2 times a week for 54 days. Weights were averaged (starting n=10) and
graphed above. Six mice were lost from the free doxorubicin group during the course
of the experiment (ending n=4), 3 mice were lost from the polyMPC-doxorubicin
group (ending n=7), 2 mice were lost from the Doxil® group (ending n=8), and 1
mouse was lost from the HBSS group (ending n=9).
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NegControl
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Figure 3 TUNEL Treated Cardiac Tissue of Doxorubicin Treated Mice
Ten mice per group (n=10) were injected with the maximum tolerated dose of free
doxorubicin (6mg/kg), Doxil® (10 mg/kg), polyMPC-doxorubicin (30 mg/kg), or
HBSS as a control. Following 54 days, or presentation of toxicity, hearts were
collected, fixed in 10% formalin, and paraffin embedded. Tissue sections were then
labeled with TUNEL for apoptotic cell identification. Positive staining for apoptotic
cells was not observed.
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Figure 4 Hematoxylin and Eosin Stained Cardiac Tissue of Doxorubicin Treated Mice
Ten mice per group (n=10) were injected with the maximum tolerated dose of free
doxorubicin (6mg/kg), Doxil® (10 mg/kg), polyMPC-doxorubicin (30 mg/kg), or
HBSS as a control. Following 54 days, or presentation of toxicity, hearts were
collected, fixed in 10% formalin, and paraffin embedded. Tissue sections were then
treated with hematoxylin and eosin stain to reveal tissue architecture and cell staining
patterns.
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Figure 5 Number of Eosin Stained Nuclei per 40x Field of Vision
Ten mice per group were injected with the maximum tolerated dose of free
doxorubicin (6mg/kg), Doxil® (10 mg/kg), polyMPC-doxorubicin (30 mg/kg), or
HBSS as a control. Following 54 days, or presentation of toxicity, hearts were
collected, fixed in 10% formalin, paraffin embedded, and treated with hematoxylin
and eosin stain. Images were collected under 40x magnification bright field
microscopy and the total numbers of nuclei in each image were counted and averaged
per group (n=10). There was a statistically significant decrease (P<0.0001) in nuclei
in cardiac tissue collected from free doxorubicin treated mice.
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Figure 6 Blood Clearance of PolyMPC-Doxorubicin
Five mice were injected into the tail vein with 6mg/kg of free doxorubicin (n=5), and
six mice were injected into the tail vein with 6 mg/kg of polyMPC-doxorubicin (n=6).
Blood samples were taken at 30 minutes, 2 hours, 6 hours, 12 hours, 24 hours, 48
hours, and 72 hours post-injection. Serum was collected from the blood and analyzed
by HPLC for doxorubicin fluorescence. By 6 hours post-injection, over 93% of free
doxorubicin has been eliminated from serum, and doxorubicin levels are not
detectable past 48 hours post-injection. At 6 hours post-injection, 40% of PolyMPCdoxorubicin is still present in serum and levels remain detectable at 72 hours postinjection.
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Figure 7 Tissue Accumulation of PolyMPC-Doxorubicin
Five mice were injected into the tail vein with 6mg/kg of free doxorubicin (n=5), and
six mice were injected into the tail vein with 6 mg/kg of polyMPC-doxorubicin (n=6).
Tissues were collected following 72 hours of treatment, frozen in liquid nitrogen, and
tissue homogenates were analyzed by HPLC for doxorubicin fluorescence.
Differences in doxorubicin fluorescence in tissues are not statistically significant
between treatment groups.
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Figure 8 Hematoxylin and Eosin Stained Hepatic Tissue of Doxorubicin Treated Mice
Ten mice per group (n=10) were injected with the maximum tolerated dose of free
doxorubicin (6mg/kg), Doxil® (10 mg/kg), polyMPC-doxorubicin (30 mg/kg), or
HBSS as a control. Following 54 days, or presentation of toxicity, livers were
collected, fixed in 10% formalin, and paraffin embedded. Tissue sections were then
treated with hematoxylin and eosin stain to reveal tissue architecture and cell staining
patterns.
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Figure 9 Tumor Accumulation of PolyMPC-Doxorubicin
MDA-MB-231 xenografts were grown in the right flank of six mice to a tumor
volume of 100-300 mm3. Mice were then injected into the tail with 6mg/kg free
doxorubicin or polyMPC-doxorubicin, or HBSS as a control. At 12 or 24 hours postinjection, tumors were collected (n=1) and analyzed by HPLC for doxorubicin
fluorescence.
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Figure 10 Tissue Weights of Lysozyme Treated Mice
Mice were injected into the tail with three architectural forms of MPC-AF546, or
lysozyme-AF546 or PBS as control. Two weeks following treatment, tissues were
collected and weighed (n=6). Lungs of mice treated with grafted MPC-AF546
weighed statistically less than lungs of mice treated with PBS (P=0.0038).
All other tissues were not statistically different weights.
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Figure 11 GFP Antibody Staining of Anterior Tibialis Muscles
Mice were injected with 10uL into the proximal anterior tibialis muscle, and 10uL
into the distal anterior tibialis muscle, on day 0 and day 7. Tissues were collected 4
weeks post-injection, fixed in formalin, and paraffin embedded. Tissue sections were
treated with anti-GFP antibody. No positive antibody staining was observed.
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Figure 12 Hematoxylin and Eosin Stained Tibialis Muscles
Mice were injected with 10uL into the proximal anterior tibialis muscle, and 10uL
into the distal anterior tibialis muscle, on day 0 and day 7. Tissues were collected 4
weeks post-injection, fixed in formalin, and paraffin embedded. Tissue sections were
treated with hematoxylin and eosin stain. No differences in tissue architecture were
observed.
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